Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 3/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297286 | 0.87 | POLB (0.63) | LMNAPOLBTP53HRH3PDE4A | |
| SCHEMBL24035605 | 0.83 | PDE4A (0.63) | LMNAKDM4EHRH3PDE4APDE4B | |
| SCHEMBL3847408 | 0.81 | MET (0.60) | LMNAKDM4EPOLBTP53HRH3 | |
| SCHEMBL3839176 | 0.81 | MET (0.60) | LMNAKDM4EPOLBTP53HRH3 | |
| SCHEMBL24035613 | 0.80 | TP53 (0.50) | LMNAKDM4EPOLBTP53HRH3 | |
| SCHEMBL27706388 | 0.80 | GRN (0.56) | LMNAPOLBTP53USP2TSHR | |
| SCHEMBL23297284 | 0.79 | MEN1 (0.60) | LMNAKDM4EPOLBTP53PDE4A | |
| SCHEMBL18169206 | 0.79 | KDM4E (0.65) | LMNAKDM4EPOLBTP53USP2 | |
| SCHEMBL11140135 | 0.77 | POLB (0.74) | LMNAKDM4EPOLBTP53HRH3 | |
| SCHEMBL23297274 | 0.77 | MEN1 (0.55) | LMNAKDM4EPOLBTP53HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149621-B1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021231572-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | LMNA 397/4885KDM4E 3412/4885POLB 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.